Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982373 | 1.00 | HIF1A (0.71) | HIF1AADORA3SLC29A1 | |
| SCHEMBL21011280 | 1.00 | HIF1A (0.71) | HIF1AADORA3SLC29A1 | |
| SCHEMBL6267089 | 1.00 | HIF1A (0.71) | HIF1AADORA3SLC29A1 | |
| SCHEMBL548570 | 1.00 | HIF1A (0.71) | HIF1AADORA3SLC29A1 | |
| SCHEMBL6267085 | 1.00 | HIF1A (0.71) | HIF1AADORA3SLC29A1 | |
| SCHEMBL17920432 | 0.91 | ADORA3 (0.67) | HIF1AADORA3SLC29A1 | |
| SCHEMBL11986894 | 0.91 | ADORA3 (0.67) | HIF1AADORA3SLC29A1 | |
| SCHEMBL28912656 | 0.90 | ADORA3 (0.69) | HIF1AADORA3SLC29A1 | |
| SCHEMBL2288240 | 0.89 | HIF1A (0.68) | HIF1AADORA3SLC29A1 | |
| SCHEMBL2288246 | 0.89 | HIF1A (0.68) | HIF1AADORA3SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| CN-120064427-A | Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging | 北京脑科学与类脑研究所 | 2025-05-30 | — | — | CN | claimed |
| CN-116445402-B | Erythroid progenitor cell expansion culture medium, expansion culture method and application | 中国科学院生态环境研究中心 | 2025-04-25 | — | — | CN | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| EP-4493729-A1 | METHODS FOR CHARACTERIZATION OF VIRAL GENOME USING BASE MODIFICATIONS | Regeneron Pharmaceuticals, Inc. (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119072547-A | Method for characterizing viral genomes using base modifications | 瑞泽恩制药公司 | 2024-12-03 | — | — | CN | claimed |
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | claimed |
| CN-112778388-A | Nucleoside analogue and preparation method and application thereof | 大连医科大学 | 2021-05-11 | — | — | CN | claimed |
| CN-112770741-A | Marker for determining sensitivity to combined anticancer agent | 学校法人庆应义塾 | 2021-05-07 | — | — | CN | claimed |
| WO-2020067228-A1 | MARKER FOR ASSESSING SENSITIVITY TO COMBINATION ANTICANCER DRUG | 学校法人慶應義塾 | 2020-04-02 | — | — | WO | claimed |
| US-7510827-B2 | Comprises nucleotide sequences probes and primers which hybridize flaviviral 3' untranslated regions for use as diagnostic tools in viral disease detection/infection; point mutations | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-03-31 | — | — | US | claimed |
| EP-1611254-A2 | COMPOSITIONS AND METHODS FOR DETECTING CERTAIN FLAVIVIRUSES, INCLUDING MEMBERS OF THE JAPANESE ENCEPHALITIS VIRUS SEROGROUP | Roche Diagnostics GmbH (DE) | 2006-01-04 | — | — | EP | claimed |
| US-20050032723-A1 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | PHARMAXIS LTD (AU) | 2005-02-10 | — | — | US | claimed |
| WO-2004092412-A2 | COMPOSITIONS AND METHODS FOR DETECTING CERTAIN FLAVIVIRUSES, INCLUDING MEMBERS OF THE JAPANESE ENCEPHALITIS VIRUS SEROGROUP | ROCHE DIAGNOSTICS GMBH (DE) | 2004-10-28 | — | — | WO | claimed |
| EP-1406667-A2 | METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS | Topigen Pharmaceutiques Inc (CA) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004511-A2 | METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS | TOPIGEN PHARMACEUTIQUE INC.. (CA) | 2003-01-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | HIF1A 886/4885ADORA3 4335/4885SLC29A1 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.